聖諾醫藥-B(02257.HK)擬發行1752.77萬股認購股份 總籌5890萬港元
格隆匯10月3日丨聖諾醫藥-B(02257.HK)發佈公吿,2024年10月2日,公司(作為發行人)與認購人(即個人投資者潘洪輝)訂立認購協議,內容有關按認購價每股股份3.36港元認購1752.77萬股認購股份。發行認購股份將無須獲得股東批准而認購股份將根據於股東特別大會上授予董事的一般授權予以發行。
認購人將購買1752.77萬股認購股份,相當於公司於本公吿日期現有已發行股本20.0%;及經配發及發行認購股份擴大的已發行股本約16.7%。待完成後,認購人將成為主要股東,因而成為公司關連人士。認購價為每股股份3.36港元,較股份於認購協議日期在聯交所所報的收市價每股4.20港元折讓20.0%。
董事認為,認購事項將有利於集團的長期發展,提供良機以籌集額外資金,加強財務狀況並擴充公司的股東基礎及資本基礎,從而促進其業務的未來增長及發展以及增加股份的流動性。認購事項所得款項總額將為約5890萬港元。認購事項所得款項淨額將約為5850萬港元及每股認購股份的淨髮行價將為3.34港元。集團擬將認購事項所得款項用作其一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.